Objective Traditional Chinese Medicine (tcm) is used in China as part of the treatment for non-small-cell lung cancer (nsclc) and often includes prescription of herbal therapy based on syndrome differentiation. Studies of various Astragalus-based Chinese medicines combined with platinum-based chemotherapy in the treatment of lung cancer are popular in East Asia, particularly in China. The aim of the present study was to perform a systematic review and meta-analysis comparing platinum-based chemotherapy alone with platinum-based chemotherapy plus Astragalus-based Chinese botanicals, with and without prescription based on syndrome differentiation, as first-line treatment for advanced nsclc.
INTRODUCTION
Cancers of the lung and bronchus are the most common causes of cancer death. The overall 5-year survival rate (sr) for patients with non-small-cell lung cancer (nsclc) is about 17.1%. Among nsclc patients, those with advancedstage disease are treated with standard therapies such as chemotherapy alone (20%), radiation therapy alone (17%), or a combination of the two (35%) [1] [2] [3] . All such therapies have both high toxicity and limited efficacy.
East Asian populations, particularly those in China, commonly use herbal medicines [Traditional Chinese Medicine (tcm)] combined with chemotherapy in an effort to reduce toxicity and preserve the highest possible quality of life in lung cancer. Of particular interest in this respect is the herb Astragalus membranaceus. A retrospective review 4 demonstrated that patients with nsclc who used Chinese herbal formulae alone could live for more than 2 years with their disease. That study found that A. membranaceus was an ingredient in 172 of the 200 analyzed Chinese herbal formulae. In vitro analysis has shown that Astragalus increases resistance to the immunosuppressive effects of chemotherapy drugs and stimulates macrophages to produce interleukin-6 and tumour necrosis factor 5, 6 .
Syndrome differentiation is the process of comprehensively analyzing clinical information obtained using the 4 main diagnostic tcm procedures: observation, listening, questioning, and pulse analyses. Syndromes can include yin, yang, exterior, interior, cold, heat, deficiency, and excess. Syndrome differentiation is used to guide the choice of tcm treatment with acupuncture and herbal formulae. Otherwise, because of convenience, oral and injection patent medicines containing chemicals extracted from Chinese herbs are also widely and empirically used by Chinese families and hospitals without a formal tcm clinical evaluation for specific syndrome differentiation 7 .
A number of randomized controlled trials have evaluated various Astragalus-based Chinese medicines combined with platinum-based chemotherapy in the treatment of lung cancer. A meta-analysis by McCullough and colleagues 8 found that Astragalus-based Chinese herbal medicine can increase the effectiveness of platinum-based chemotherapy. However, an updated comprehensive review of tcm in the treatment of advanced nsclc has yet to be performed. In the present study, we systematically evaluated the results of selected randomized controlled trials to elucidate whether tcm treatment based on syndrome differentiation is more effective than Astragalus-based therapy without such a formal evaluation.
METHODS

Search Strategy
We 
Eligibility Criteria
Relevant clinical trials were manually selected when they met these criteria:
n Study patients had nsclc previously untreated by chemotherapy alone n The study was a comparison of platinum-based chemotherapy alone or with Astragalus-based herbal therapy (with or without tcm syndrome differentiation) in the first line n The study had sufficient data, especially survival data, for extraction n The study scored 2 or better on the Jadad quality scale Systematic reviews and meta-analysis were excluded.
Date Extraction and Validity Assessment
Data extracted from eligible articles for analysis had to include the overall survival (os) rate 9 ; the 1-year, 2-year, 3-year srs; performance status (ps); overall response rate (orr); and percentage of patients experiencing grades 3 and 4 toxicities. We also extracted basic data in the form of the first author's name, the year of publication, lung cancer stages, and number of patients. The screening and review were performed by 2 independent reviewers searching the literature and extracting data independently. Mismatches between reviewers were resolved by consensus after a 3rd check and discussion between the reviewers 10 . application (version 11.0: StataCorp LP, College Station, TX, U.S.A.) 11 . Subgroup analyses based on heterogeneity between trials used the chi-square-based Q statistic and were considered statistically significant at a p value less than 0.05 or I 2 greater than 50% 12 . In the presence of heterogeneity, data were analyzed in a random-effects model; otherwise, a fixed-effects model was used. A statistical test resulting in a p value less than 0.05 was considered to indicate a statistically significant difference. A rr less than 1 reflected a favourable response, sr (1-, 2-, or 3-year), or toxicity in the tcm plus chemotherapy arm.
Publication bias was evaluated using Begg funnel plots, which examine associations between effect estimates and their variances (p > 0.05 indicates no correlation between studies) and Egger tests, which are more specific 13, 14 . All p values were 2-sided. All confidence intervals (cis) had a 2-sided probability coverage of 95%.
RESULTS
Study Selection
The initial search, performed in March 2014, found 372 articles. Titles and abstracts were screened, and 178 articles were excluded because they did not meet the inclusion criteria; the remaining 194 full-text articles were reviewed for inclusion. Subsequently, 142 articles were excluded because of a lack of sufficient survival data for extraction, and 34 articles were excluded because of inferior quality 15 . In the end, seventeen clinical trials (1552 patients) reported in full-text publication were eligible. One clinical trial was designed to use Astragalus alone combined with chemotherapy; the other sixteen were designed to use tcm containing Astragalus as the principal drug together with chemotherapy. The quantitative 5-point Jadad scale was used to assess the quality of the included trials ( Figure 1 , Table i) .
It is important to note that, in the included studies, Astragalus-based herbal formulae were developed based on syndrome differentiation and were prescribed by an authoritative and experienced chief physician, with the herbal dosages being based on the Chinese pharmacopoeia.
Once the diagnosis is made, the appropriate formula is prescribed and decocted (Chinese drug decoction has 3 steps: soaking, decocting, and concentrating). The formula is given twice daily. For patent oral and injection medicines, use must be based on the manufacturer's instructions; administration is not based on syndrome differentiation.
Publication Bias
Neither the Begg funnel plot (p = 0.591 for orr) nor the Egger test (p = 0.089 for 1-year sr; p = 0.383 for 2-year sr; p = 0.113 for ps; p = 0.075 for orr) revealed any obvious asymmetry in the included trials.
ORR
Five of the included trials (549 patients) reported os. Pooled hr for os favoured the combination of an Astragalus-based formula with chemotherapy over chemotherapy alone (hr: 0.61; 95% ci: 0.42 to 0.89; p = 0.011). Subgroup analyses showed that the os was significantly improved in the arms using an Astragalus-based herbal formula (hr: 0.40; 95% ci: 0.26 to 0.61; p < 0.001), but not in those using an Astragalus-based injection (hr: 0.80; 95% ci: 0.59 to 1.10; p = 0.169; Figure 2 ). 
One-Year SR
Two-Year SR
Five trials (533 patients) reported 2-year srs. Using a fixedeffects model, the pooled rr for 2-year sr favoured the combination of an Astragalus-based product and chemotherapy over chemotherapy alone (rr: 0.33; 95% ci: 0.23 to 0.47; p < 0.001). Subgroup analyses showed that the 2-year sr was slightly improved with an Astragalus-based injection (rr: 0.56; 95% ci: 0.36 to 0.87; p = 0.01) and significantly improved with Astragalus-based herbal formulae [rr: 0.20; 95% ci: 0.11 to 0.36; p < 0.001; Figure 3(B) ].
Three-Year SR
Three trials (360 patients) reported 3-year srs. Using a fixed-effects model, the pooled rr for 3-year sr favoured the combination of an Astragalus-based product and chemotherapy over chemotherapy alone (rr: 0.30; 95% ci: 0.17 to 0.53; p < 0.001). Subgroup analyses were not available because of limited data [ Figure 3(C) ].
Karnofsky PS
Eight trials reported Karnofsky ps data. Using a fixedeffects model, the pooled rr for ps favoured the combination of an Astragalus-based product and chemotherapy Figure 4 ).
Tumour ORR
The Response Evaluation Criteria in Solid Tumors defines tumour orr as the sum of the partial and complete response rates. Twenty-six trials included orr data. Using a fixed-effects model, the pooled orr data significant in favoured the combination of an Astragalus-based product and chemotherapy over chemotherapy alone (rr: 0.79; 95% ci: 0.71 to 0.89; p < 0.001). In addition, the subgroup analyses showed that the tumour orr was significantly improved with the Astragalus-based herbal formulae based on syndrome differentiation (rr: 0.75; 95% ci: 0.62 to 0.90; p = 0.002) and with the Astragalus-based injection (rr: 0.80; 95% ci: 0.68 to 0.93; p = 0.004), but not with the Astragalus-based oral patent medicines (rr: 0.85; 95% ci: 0.65 to 1.11; p = 0.234).
Safety
Adverse events were evaluated using the U.S. National Cancer Institute's Common Toxicity Criteria, version 2, or its Common Terminology Criteria for Adverse Events (version 3). Fourteen trials reported grades 3 and 4 toxicities. Compared with the combination of an Astragalus-based product and platinum-based chemotherapy, platinum-based chemotherapy alone was associated with more toxicities (anemia, neutropenia, thrombocytopenia, fatigue, poor appetite, nausea, vomiting; Table ii) .
DISCUSSION
The present study reviewed seventeen clinical trials reported in full-text publication and comprising 1552 patients. The combination of an Astragalus-based product and chemotherapy was associated with significant increases in os, 1-year sr, 2-year sr, 3-year sr, ps, and tumour orr. Notably, side effects including anemia, neutropenia, thrombocytopenia, fatigue, poor appetite, nausea, and vomiting were significantly more frequent with platinum-based chemotherapy alone than with the combination of an Astragalus-based product and chemotherapy.
Astragalus occupies an important place in the tcm system. It has been used for almost all diseases caused by chi deficiency, which is associated with cellular immune dysfunction. Chi is understood to be the vital energy that maintains blood circulation, warms the body, and fights diseases. In cancer patients, chi deficiency is the most common symptom according to the concept of tcm. Symptoms of chi deficiency include fatigue, lack of appetite, and depression 33 .
Our meta-analysis demonstrates the potential clinical efficacy of Astragalus-based tcm combined with platinumbased chemotherapy in the treatment of advanced nsclc. Treatment based on syndrome differentiation is a characteristic of tcm diagnosis and treatment. Herbal formulae prescribed by syndrome differentiation can be different Traditional Chinese Medicine containing Astragalus only. Pts = patients; OS = overall survival; ORR = overall response rate; PS = performance status; NA = not applicable.
FIGURE 2
Forest plot of overall survival after treatment with Astragalus and platinum-based chemotherapy compared with platinum-based chemotherapy alone. Subgroups consider oral and injection herbal formulas containing Astragalus. hr = hazard ratio; CI = confidence interval.
for each patient, as is typical of tcm. In the tcm system, patients are prescribed botanicals based on specific individual variations. Chinese patent medicines and injections generally consist of extracted and condensed elements of herbs in the form of pills, capsules, electuaries, or injectable liquids 34 ; they are not based on individual syndrome differentiation. Our study is hypothesis-generating, in that, compared with Astragalus-based oral and injection patent medicines, Astragalus-containing herbal formulae based on syndrome differentiation were associated with enhanced efficacy and tolerability of platinum-based chemotherapy in patients with nsclc.
Several limitations have to be considered when interpreting our results. First, the data extracted from the included publications were not individual patient data; they did not include tumour molecular analysis; and no single tcm provider evaluated all patients. A meta-analysis based on individual patient data, with their associated molecular, clinical, and pathologic findings, would allow for a more firm conclusion. Second, none of the herbal formulae or tcm practices used in the included studies are specific or reproducible. The study populations were limited to East Asian patients, and the results require replication in other patients from varied backgrounds. Additional high-quality, controlled, and reproducible randomized controlled trials are warranted; the results reported here should be seen as hypothesis-generating only.
CONCLUSIONS
The relatively low success rates in the treatment of advanced and metastatic nsclc have prompted the scientific community to adopt novel and innovative approaches in seeking more effective and less toxic treatment regimens. Astragalus-based Chinese herbal formulations, especially when based on individualized tcm evaluation with its resultant syndrome differentiation, could potentially offer an avenue for future study. 
